POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Sodium chloride provides sodium ions, which are critical for electrolyte balance and osmotic pressure regulation.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys. Sodium is also excreted mainly by the kidneys, with small amounts lost in feces and sweat. No significant hepatic metabolism. |
| Excretion | Primarily renal (>90% of absorbed potassium is excreted by the kidneys, with about 80-90% in urine and 10% in feces). Renal elimination follows glomerular filtration and distal tubular secretion, with minimal biliary excretion. |
| Half-life | The terminal elimination half-life of potassium is approximately 3-5 hours in patients with normal renal function. However, this can be clinically misleading as potassium distribution and excretion are complex; the half-life may be prolonged in renal impairment. |
| Protein binding | Potassium is not significantly bound to plasma proteins; protein binding is negligible (approximately 0-5%). |
| Volume of Distribution | Volume of distribution for potassium is approximately 0.2-0.4 L/kg in healthy individuals, reflecting its predominantly extracellular distribution. Total body potassium is about 50 mEq/kg, but Vd for exchangeable potassium is about 7 L/kg; the small Vd for IV administered potassium indicates it does not rapidly enter cells. |
| Bioavailability | Oral potassium chloride is well absorbed with bioavailability estimated at 100% (no significant first-pass metabolism). Intravenous administration provides 100% bioavailability. |
| Onset of Action | Onset of action following intravenous administration of potassium chloride is rapid, typically within minutes (5-10 minutes) as serum potassium levels begin to rise. Oral onset is slower, usually 1-2 hours after ingestion. |
| Duration of Action | Duration of effect depends on dose and renal function. After IV administration, the effect on serum potassium lasts several hours, typically 4-6 hours. Continuous infusion maintains steady levels. Oral potassium's effect can last 6-8 hours. |
Intravenous infusion; typical maintenance dose is 10-20 mEq/hour (equivalent to approximately 200-400 mL/hour of this solution), not to exceed 40 mEq/hour or 200 mEq/day, depending on serum potassium levels and clinical status. Concentration should not exceed 40 mEq/L when administered via peripheral line; central line may be used for higher concentrations.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: Use with caution and monitor potassium levels; reduce dose by 25-50%. GFR <30 mL/min: Contraindicated unless severe hypokalemia is present with careful monitoring; dose reduction >50% may be required. Avoid in oliguric or anuric patients. |
| Liver impairment | No specific pediatric guidelines; however, in hepatic impairment, electrolyte disturbances are common. Monitor potassium closely; no dose adjustment specified based on Child-Pugh score. Use with caution in cirrhosis and ascites due to risk of hyperkalemia from renal impairment or medications. |
| Pediatric use | Dose based on weight and serum potassium. Typical maintenance: 0.5-1 mEq/kg/day. For hypokalemia: 1-2 mEq/kg over 1 hour, not to exceed 0.5-1 mEq/kg/hour or 40 mEq/L concentration. Administer via central line if concentration >40 mEq/L. Titrate to response and monitor ECG. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium is a normal component of breast milk. Exogenous potassium from intravenous infusion is unlikely to significantly increase milk potassium levels. No M/P ratio is available. Potassium chloride is considered compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride is a normal constituent of body fluids and at standard infusion rates does not pose a teratogenic risk. However, maternal hyperkalemia from excessive administration can cause fetal arrhythmias or distress. No specific trimester-associated risks are documented; use caution in all trimesters. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Administration of undiluted potassium chloride can result in fatal cardiac arrhythmias. Use only in patients with normal renal function and with careful monitoring of serum potassium levels.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Renal failure with oliguria or anuria","Addison's disease","Severe hemolytic reactions","Hyperadrenocorticism","Concurrent use of potassium-sparing diuretics"]
| Precautions | Use with caution in patients with renal impairment, heart disease, or conditions predisposing to hyperkalemia (e.g., metabolic acidosis, adrenal insufficiency). Monitor serum potassium and sodium levels, ECG, and fluid balance. Rapid infusion may cause hyperkalemia and cardiac arrest. Avoid in patients with elevated serum potassium levels. |
Loading safety data…
| Start at lower end of dosing range due to age-related decline in renal function and increased risk of hyperkalemia (e.g., 10 mEq/hour); monitor serum potassium and renal function closely. Avoid rapid infusion; consider using half the usual maintenance rate in patients >65 years with impaired renal function. |
| Fetal Monitoring | Monitor maternal serum potassium levels, renal function, urine output, and electrocardiogram for signs of hyperkalemia (peaked T waves, widened QRS). Fetal heart rate monitoring is indicated in cases of maternal hyperkalemia or fluid overload. |
| Fertility Effects | No known adverse effects on fertility. Potassium chloride at therapeutic doses does not impact reproductive function. |